VP / Head, Oncology R&D
Description
Vice President, Oncology TA R&D Head
- Lead BOTH Drug Discovery and Clinical Research – team of ~50 people
- Unique and attractive company culture
- Retained Search
Cornerstone Search Group is pleased to have been retained again by a profitable $1.5Bn+, high-market cap, fully integrated, oncology-focused pharma with a uniquely positive work environment that reflects its European HQ country’s renowned culture. With a product portfolio featuring a current oncology blockbuster and the upcoming launch of another anticipated oncology blockbuster, our client is in a very active phase of building out their pipeline through both extensive in-house research across multiple modalities (ADC / bsAb / small molecule) and in-licensing efforts. This unique VP-level leadership role is responsible for Oncology R&D strategy and execution across both drug discovery and clinical development. Our client is seeking an entrepreneurial MD or MD/PhD who is presently a Senior Director (or higher) in the pharma industry, ideally has both industry oncology clinical development experience as well as academic or industry lab research experience, values working with like-minded high EQ people in a high collaboration / low bureaucracy environment, and has a passion for oncology drug development.
Location
New York Metro Area (on-site or hybrid)
This role is based in our client’s New York Metro Area office and will require occasional travel to its European headquarters. Our client prefers local candidates (i.e., NJ, NY, PA, CT) or candidates along the Eastern seaboard (e.g., MA, MD, DC, NC, DE).
WORK AUTHORIZATION: Our client will consider candidates who require an H-1B transfer, TN-Visa, or equivalent, as well as Green Card / Permanent Resident sponsorship.
Features
5 ATTRACTIVE FEATURES:
- Uniquely attractive opportunity to join a growing, profitable, publicly-traded company with $1.5Bn+ in revenue and a $5Bn+ market cap that still retains a small company feel with very few layers.
- Our client’s marketed products include a fast-growing cancer blockbuster and a Phase III clinical candidate that is anticipated to also be a blockbuster.
- This company’s culture reflects its HQ country’s reputation for having one of the world's most content populations.
- We have partnered with this client multiple times before, so we know them quite well. The people that we have helped them hire have been very happy with the culture and impressed with executive management and their peers.
- You will play a key role in the leadership of their US site across all functions.
Responsibilities
RESPONSIBILITIES in a NUTSHELL:
- Responsible for Oncology Therapeutic Area strategy and implementation of said strategy.
- Accountable for the continued building and development of the oncology pipeline by leading both the Oncology Research and Oncology Clinical Development teams (~50 people as of now).
- Oversee the design and execution of oncology clinical trials strategy that incorporate global regulatory, medical, and commercial considerations.
- Lead and/or support cross-functional teams working across Discovery, Clinical Development, Medical Affairs, Regulatory, Compliance, and Commercial.
- Develop scientific relationships with academic research institutions and KOLs.
Qualifications / Requirements
DESIRED SKILLS / QUALIFICATIONS / EXPERIENCE / BEHAVIORS:
- MD / MBBS / DO / MBChB required. Oncology or Immunology medical training is a plus.
- PhD is a plus.
- Previous pharma industry experience at the Senior Director or higher level, including leading early stage oncology clinical trials.
- Previous experience in lab research or lab leadership (academia or industry) is a plus.
- High emotional intelligence.
- Ability to communicate in a clear and concise manner.
Contact
Recently Completed Retained Searches by Cornerstone
REPRESENTATIVE RETAINED SEARCH ASSIGNMENTS:- CEO | specialty pharma start-up
- CEO | regenerative medicine start-up
- US CEO | established European small pharma
- President/US Commercial Head | generics pharma
- CMO | late-stage public biotech
- CMO | mid-size pharma
- CSO | mid-size global biotech
- SVP, Head of Global Medical Affairs | mid-size oncology company
- SVP, Head of Global Clinical Development | multi-TA mid-size pharma
- SVP, Head of Global Regulatory Affairs | late-stage Israeli biotech
- Group VP, Global Commercial Head | API Business Unit | Indian pharma
- VP, Data Science RWE | Top 5 Pharma
- VP, Head of Regulatory Affairs | Boston biotech
- VP, US Head of Regulatory Affairs | Top 20 Pharma
- VP, Head of R&D Operations | Boston biotech
- VP, Head of HEOR (Health Economics & Outcomes Research | Top CNS specialty pharma
- VP, Head of US HEOR & RWE | Top 5 Pharma
- VP, Head of Real-World Evidence | Top 5 pharma
- VP, Head of US HEOR | Top Oncology Pharma
- ED, Head of HEOR | Top West Coast Pharma
- VP, Head of Global Market Access | Top Oncology Specialty Pharma
- VP, Head of US Market Access | High-profile late stage biotech
- VP, Head of US Market Access | West Coast Late-Stage Public Biotech
- VP, Head of Heme/Onc Clinical Research | Public oncology biotech
- VP, Head of Clinical Development | late-stage anti-infectives UK pharma
- VP, Head of Global Drug Safety & PV | Chinese oncology biotech
- ED, Head of Clinical Operations | British VC-backed biotech
- ED, Global Commercial Strategy Franchise Head | Top rare disease Boston pharma
- ED, Head of Global Clinical Pharmacology | Public oncology biotech
- ED, Head of Global HEOR | Large US Pharma
- Head, Patient Advocacy | European commercial-stage rare disease biotech
- Medical Directors (Director/SD/ED levels) in Translational Medicine / Clinical Development / Medical Affairs / Drug Safety: 75+ retained assignments
- HEOR/RWE/Market Access (AD/Director/SD/ED levels): 100+ retained assignments
Cornerstone's Privacy Policy
Cornerstone Search Group considers all inquiries, resume submissions, and any other personal information submitted to us as confidential information. This information will not be shared with any parties outside of Cornerstone Search Group without your prior permission.
Keywords
cancer CAR-T antibody-drug conjugates bi-specific bispecific TKI solid tumor I-O immuno-oncology immunooncology